Michael Hochman

Asst Prof Hematology @EmoryMedicine @WinshipatEmory. @DukeMedSchool, IM residency @UWMedicine, Heme fellowship @hopkinskimmel @HopkinsHeme. 🏳️‍🌈

[Michael Hochman @mjhochman]

Managing Myeloid Neoplasms With Low-Risk Phenotype and High-Risk Mutations Is a New Frontier https://t.co/A0r048kKz2

[Michael Hochman @mjhochman]

@HopkinsHeme @LydiaPecker @BloodClotDoc @JenniferYuiMD @mstreif1 @DocsDock200 SO well deserved!

[Michael Hochman @mjhochman]

@MariaAmaya_27 a beautiful family--congrats!!!

[Michael Hochman @mjhochman]

Excited to share my review of higher-risk MDS, published in Clinical Lymphoma, Myeloma and Leukemia and written with the amazing @AmyDeZern!:
https://t.co/H8HQ9i1qO1…
"Hopefully the MDS community now sits at a turning point in history for HR-MDS."
@ElsevierConnect

[Chris Hourigan @DrChrisHourigan]

Congratulations to @mjhochman and co-authors: https://t.co/F8yPmeFG26

[Nancy Gillis 🆖☮️ @nancykgillis]

📰Our new contribution using the National MDS Study Cohort. Led by the amazing @AmyDeZern @MikkaelSekeres and many many others. #MDSsm
Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions https://t.co/5thERwt9RG

[Michael Hochman @mjhochman]

@Hopkins_HemOnc @saumarai @WarrierMD @kamarroneMD @redcell_doc Honored to have these phenomenal Hopkins heme onc fellows follow in our footsteps!

[Johns Hopkins Hematology and Oncology Fellowship @Hopkins_HemOnc]

We are thrilled, excited, and proud to announce our chiefs for AY24. Dr. @saumarai, Dr. @WarrierMD, and Dr. Catherine Wilbur. #1Fellowship1Family. Looking forward to the great things you will accomplish in your roles.

[Robert Brodsky @DocsDock200]

Hematology workforce shortage? How we got here and how we are addessing it. #ASHTrainee#classicalheme#HFFTP https://t.co/p98wYsNve2

[Blood Journals Portfolio @BloodPortfolio]

How I prevent #GVHD in high-risk patients: posttransplant cyclophosphamide and beyond https://t.co/XFS6IYRdjs

[Michael Hochman @mjhochman]

@Dr_AmerZeidan What prompted the marrow in the first place? Is this a case of #AMLsm overdiagnosis?? 😆

[Michael Hochman @mjhochman]

@LaurenBzak @DocsDock200 I wish I knew you were there! Yes, let's catch up next year. Looks like we may be treating the same disease.

[Michael Hochman @mjhochman]

Exhausted but rejuvinated all the same from a wonderful #ASH22. Great seeing colleagues and friends from all walks of life, presenting abstracts on MRD and ontogeny in AML, and seeing the new ASH mascots that Dr. Rob Brodsky @DocsDock200 designed as he leads ASH in 2023.

[Michael Hochman @mjhochman]

Many thanks to @AmyDeZern, without whom I would not have been able to present this work. She's an outstanding mentor, clinician, and thought leader.

[Johns Hopkins Hematology @HopkinsHeme]

Congratulations to @HopkinsHeme Division Director Dr. Robert Brodsky as he takes on his new role as ASH President 2023! With his inspiring leadership, hematology is in great hands. We can’t wait to see what this next year will bring!! 🩸🌟
#HemeDreamTeam @DocsDock200

[Michael Hochman @mjhochman]

@jeff_keelan That's a good one.

[Michael Hochman @mjhochman]

Hematology: always leading the way with the least pronounceable new drug names in medicine. #ASH22

[Michael Hochman @mjhochman]

@IbodengG Completely agree-it was excellent and very novel! Don't judge a drug by its name 😂

[Keith W Pratz MD @PratzKW]

⁦@DrChrisHourigan⁩ presenting words of wisdom from our great mentor Judy Karp at the #ASH22 AML education session.

[Elli Papaemmanuil, PhD @PapaemmanuilLab]

It is clear. If there is one thing we owe to patients, hemato-oncologists, pathologists, clinical trialists, scientists & regulators is to unify the CAC/ICC & WHO classification ASAP. Why wait for the next revision? #ASH22 inspiration